June 24, 2024

Stream Health Care

It Looks Good On You

What New Journey Health Technology Group Co.,LTD’s (SZSE:002219) P/S Is Not Telling You

3 min read

With a median price-to-sales (or “P/S”) ratio of close to 1.9x in the Healthcare industry in China, you could be forgiven for feeling indifferent about New Journey Health Technology Group Co.,LTD’s (SZSE:002219) P/S ratio of 2.3x. Although, it’s not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

See our latest analysis for New Journey Health Technology GroupLTD

SZSE:002219 Price to Sales Ratio vs Industry May 14th 2024

What Does New Journey Health Technology GroupLTD’s Recent Performance Look Like?

The revenue growth achieved at New Journey Health Technology GroupLTD over the last year would be more than acceptable for most companies. Perhaps the market is expecting future revenue performance to only keep up with the broader industry, which has keeping the P/S in line with expectations. If that doesn’t eventuate, then existing shareholders probably aren’t too pessimistic about the future direction of the share price.

Want the full picture on earnings, revenue and cash flow for the company? Then our free report on New Journey Health Technology GroupLTD will help you shine a light on its historical performance.

What Are Revenue Growth Metrics Telling Us About The P/S?

There’s an inherent assumption that a company should be matching the industry for P/S ratios like New Journey Health Technology GroupLTD’s to be considered reasonable.

If we review the last year of revenue growth, the company posted a terrific increase of 15%. The latest three year period has also seen a 24% overall rise in revenue, aided extensively by its short-term performance. Accordingly, shareholders would have probably been satisfied with the medium-term rates of revenue growth.

Comparing that to the industry, which is predicted to deliver 17% growth in the next 12 months, the company’s momentum is weaker, based on recent medium-term annualised revenue results.

With this in mind, we find it intriguing that New Journey Health Technology GroupLTD’s P/S is comparable to that of its industry peers. Apparently many investors in the company are less bearish than recent times would indicate and aren’t willing to let go of their stock right now. They may be setting themselves up for future disappointment if the P/S falls to levels more in line with recent growth rates.

What We Can Learn From New Journey Health Technology GroupLTD’s P/S?

Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

We’ve established that New Journey Health Technology GroupLTD’s average P/S is a bit surprising since its recent three-year growth is lower than the wider industry forecast. Right now we are uncomfortable with the P/S as this revenue performance isn’t likely to support a more positive sentiment for long. Unless the recent medium-term conditions improve, it’s hard to accept the current share price as fair value.

There are also other vital risk factors to consider and we’ve discovered 3 warning signs for New Journey Health Technology GroupLTD (1 is a bit concerning!) that you should be aware of before investing here.

Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Valuation is complex, but we’re helping make it simple.

Find out whether New Journey Health Technology GroupLTD is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.


Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.